AP26113- Pharmacodynamics
Dec 13,2019
Brigatinib (AP26113) is a tyrosine kinase inhibitor with in vitro activity against a number of kinases, including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), FLT-3, and also epidermal growth factor receptor (EGFR) deletion and point mutations. Autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signalling proteins STAT3, AKT, ERK1/2, and S6 is inhibited by Brigatinib in vitro and in vivo [1].
In in vitro kinase assays, Brigatinib had potent activity against ALK (IC50 0.6 nmol/L), including the mutant variants C1156Y (0.6 nmol/L), F1174L (1.4 nmol/L), L1196M (1.7 nmol/L), G1202R (4.9 nmol/L) and R1275Q (6.6 nmol/L). The drug also demonstrated activity against ROS1, FLT3, mutant variants of FLT3 (D835Y) and EGFR (L858R; IC50 1.5–2.1 nmol/L) and to a lesser extent EGFR with a T790M resistance mutation (L858R/T790M), native EGFR, IGF-R1, and INSR (IC50 values 29–160 nmol/L) [2].
Brigatinib inhibited growth of various anaplastic large cell lymphoma (ALCL) and NSCLC cell lines expressing NPM-ALK or EML4-ALK fusions [growth inhibition of 50% of cells (GI50) 4–31 nmol/L]; the ALK phosphorylation IC50 of the drug in these cell lines was 1.5–12 nmol/L. GI50 values for Brigatinib ranged between 503 and 2387 nmol/L in 3 ALK-negative ALCL and NSCLC cell lines [2].
Brigatinib had substantial in vitro activity against a panel of 17 ALK mutants that confer resistance to Crizotinib, Ceritinib, And Alectinib (IC50 of Brigatinib 9–184 nmol/L). Brigatinib had 2.2- to 77-fold more potency than Crizotinib (IC50 170–1109 nmol/L) against all but the L1198F mutant, was C3-fold more potent than Ceritinib against L1152R/P, C1156Y, L1198F, and G1269A and C3-fold more potent than Alectinib against L1152R, I1171N, V1180L, L1196M, G1202R, and G1269A [2].
Oral Brigatinib 10, 25 or 50 mg/kg administered once daily inhibited tumour growth dose dependently in ALK positive Karpas-299 (ALCL) and H2228 (NSCLC) xenograft mouse models [3].
In a murine orthotopic brain tumour model in which ALK-positive H2228 (NSCLC) cells were injected intracranially to form tumours in the brain, daily oral administration of Brigatinib 25 and 50 mg/kg prolonged median survival to 62 and [64 days, respectively, compared to crizotinib 100 mg/kg/day (median survival 47.5 days) and vehicle (median survival 28 days) [3].
On the 28th of April 2017, Brigatinib (AP26113) received its first global approval in the USA for the treatment of patients with metastatic ALK-positive NSCLC.
References
1.Anthony M. Brigatinib: First Global Approval[J]. Drugs, 2017, 77:1131–1135
2.Zhang S, Anjum R, Squillace R. The potent ALK inhibitor Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models[J]. Clin Cancer Res. 2016, 22(22):5527–38.
3.Gettinger SN, Bazhenova LA, Langer CJ. Activity and safety of Brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial[J]. Lancet Oncol. 2016, 17(12):1683–96.
- Related articles
- Related Qustion
- AP26113 as inhibitor of cancer biomarkers Oct 10, 2019
AP26113, or Brigatinib, is a novel, synthetic, orally active and potent small-molecule inhibitor of anaplastic lymphoma kinase (ALK). ALK is a receptor tyrosine kinase of the insulin receptor family.
Afatinib dimaleate (Tovok; BIBW2992; Gilotrif) is a salt form of Afatinib. Afatinib is a second-generation, orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases.....
Dec 13,2019InhibitorsNeratinib is an oral pan HER inhibitor that irreversibly inhibits the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2, and HER4.....
Dec 13,2019InhibitorsAP26113
1197958-12-5You may like
- AP26113
-
- $0.00 / 1kg
- 2024-08-15
- CAS:1197958-12-5
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 20tons
- Brigatinib(ap26113)
-
- $0.00 / 1g
- 2024-03-12
- CAS:1197958-12-5
- Min. Order: 1g
- Purity: 98% HPLC
- Supply Ability: 1kg
- AP26113
-
- $150.00 / 1kg
- 2023-06-07
- CAS:1197958-12-5
- Min. Order: 1kg
- Purity: 99.9%
- Supply Ability: 10000MT